VIATRIS INC. Goodwill, Translation and Purchase Accounting Adjustments
VIATRIS INC. (VTRS) reported Goodwill, Translation and Purchase Accounting Adjustments of -$100.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments · last filed 2026-08-06
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for the quarter ending 2026-06-30 was -$38.00M, a 113.28% decline year-over-year.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for the quarter ending 2026-03-31 was -$62.30M, a 123.46% decline year-over-year.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for the quarter ending 2025-12-31 was $23.90M.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for the quarter ending 2025-09-30 was -$17.50M, a 107.42% decline year-over-year.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for fiscal 2025 was $558.20M.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for fiscal 2024 was -$432.30M, a 474.61% decline from fiscal 2023.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for fiscal 2023 was $115.40M, a 0.00% change from fiscal 2022.
- VIATRIS INC. goodwill, translation and purchase accounting adjustments for fiscal 2022 was $115.40M.
| Period end | Goodwill, Translation and Purchase Accounting Adjustments 3 month | Goodwill, Translation and Purchase Accounting Adjustments 6 month | Goodwill, Translation and Purchase Accounting Adjustments 9 month | Goodwill, Translation and Purchase Accounting Adjustments 12 month | Goodwill, Translation and Purchase Accounting Adjustments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$38.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$100.30M 10-Q · filed 2026-08-06 | -$76.40M derived: sum of 3 quarters · filed 2026-08-06 | -$93.90M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$62.30M 10-Q · filed 2026-05-07 | -$38.40M derived: sum of 2 quarters · filed 2026-05-07 | -$55.90M derived: sum of 3 quarters · filed 2026-05-07 | $230.30M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | $23.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.40M derived: sum of 2 quarters · filed 2026-02-26 | $292.60M derived: sum of 3 quarters · filed 2026-02-26 | $558.20M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$17.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $268.70M derived: sum of 2 quarters · filed 2025-11-06 | $534.30M 10-Q · filed 2025-11-06 | $105.90M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-06-30 | $286.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $551.80M 10-Q · filed 2025-08-07 | $123.40M derived: sum of 3 quarters · filed 2026-02-26 | $359.20M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-03-31 | $265.60M 10-Q · filed 2025-05-08 | -$162.80M derived: sum of 2 quarters · filed 2026-02-26 | $73.00M derived: sum of 3 quarters · filed 2026-02-26 | $26.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | -$428.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$192.60M derived: sum of 2 quarters · filed 2026-02-26 | -$239.20M derived: sum of 3 quarters · filed 2026-02-26 | -$432.30M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $235.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $189.20M derived: sum of 2 quarters · filed 2024-11-07 | -$3.90M 10-Q · filed 2024-11-07 | $288.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-06-30 | -$46.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$239.70M 10-Q · filed 2024-08-08 | $52.80M derived: sum of 3 quarters · filed 2025-02-27 | -$135.70M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-03-31 | -$193.10M 10-Q · filed 2024-05-09 | $99.40M derived: sum of 2 quarters · filed 2025-02-27 | -$89.10M derived: sum of 3 quarters · filed 2025-02-27 | -$129.80M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-12-31 | $292.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $104.00M derived: sum of 2 quarters · filed 2025-02-27 | $63.30M derived: sum of 3 quarters · filed 2025-02-27 | $115.40M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$188.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$229.20M derived: sum of 2 quarters · filed 2023-11-08 | -$177.10M 10-Q · filed 2023-11-08 | $1.09B derived: sum of 4 quarters · filed 2024-02-28 | |
| 2023-06-30 | -$40.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $11.40M 10-Q · filed 2023-08-07 | $1.27B derived: sum of 3 quarters · filed 2024-02-28 | $780.60M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2023-03-31 | $52.10M 10-Q · filed 2023-05-08 | $1.31B derived: sum of 2 quarters · filed 2024-02-28 | $821.30M derived: sum of 3 quarters · filed 2024-02-28 | $349.40M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-12-31 | $1.26B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $769.20M derived: sum of 2 quarters · filed 2024-02-28 | $297.30M derived: sum of 3 quarters · filed 2024-02-28 | $115.40M 10-K · filed 2024-02-28 | |
| 2022-09-30 | -$493.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$965.40M derived: sum of 2 quarters · filed 2022-11-07 | -$1.15B 10-Q · filed 2022-11-07 | -$1.40B derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | -$471.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$653.80M 10-Q · filed 2022-08-08 | -$908.90M derived: sum of 3 quarters · filed 2024-02-28 | -$1.08B derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | -$181.90M 10-Q · filed 2022-05-09 | -$437.00M derived: sum of 2 quarters · filed 2024-02-28 | -$611.20M derived: sum of 3 quarters · filed 2024-02-28 | -$540.00M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$255.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$429.30M derived: sum of 2 quarters · filed 2024-02-28 | -$358.10M derived: sum of 3 quarters · filed 2024-02-28 | -$651.20M 10-K · filed 2024-02-28 | |
| 2021-09-30 | -$174.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$103.00M derived: sum of 2 quarters · filed 2021-11-08 | -$396.10M 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $71.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$221.90M 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | -$293.10M 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | -$528.90M 10-K · filed 2023-02-27 | $648.90M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $648.90M 10-K · filed 2022-02-28 | -$157.20M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |